Peripheral Artery Disease and Diabetes

Peripheral artery disease (PAD) is 2 to 4 times more common in adults with diabetes than in non-diabetic peers and is a major risk factor for foot ulcers, infections, and lower-extremity amputation. The same atherosclerotic disease process that affects coronary arteries also affects leg arteries — but adults with diabetes face accelerated progression due to hyperglycemia, hypertension, dyslipidemia, and the high prevalence of smoking. The diabetes-specific challenge is that peripheral neuropathy can mask the classic claudication pain — adults with both PAD and neuropathy may have minimal symptoms despite severe disease. This silent progression is one reason the American Diabetes Association recommends ankle-brachial index (ABI) screening for adults with diabetes age 50+ or with risk factors. Treatment ranges from smoking cessation and supervised exercise to medications and revascularization procedures. PAD is also a marker of systemic atherosclerosis — adults with PAD have 3-5 times higher cardiovascular mortality, so aggressive risk factor management is essential.

The Scope of the Problem

Symptoms and Diagnosis

• Classic claudication: cramping calf pain with walking, resolves with rest.
• Atypical symptoms: leg fatigue, weakness, heaviness; often missed.
• Rest pain: pain at rest in severe disease; often worse at night when leg is elevated.
• Critical limb ischemia: rest pain, non-healing wounds, gangrene; emergency.
• Silent PAD: substantial percentage of diabetes patients have advanced PAD without symptoms due to neuropathy.
• Physical exam findings: diminished pulses, hair loss on legs, cool feet, slow capillary refill.

Ankle-Brachial Index (ABI) Screening

• Compares ankle systolic BP to arm systolic BP.
• Normal: 1.0-1.4.
• Borderline: 0.91-0.99.
• Mild PAD: 0.71-0.90.
• Moderate PAD: 0.41-0.70.
• Severe PAD: ≤0.40.
• Greater than 1.4 suggests calcified arteries (common in diabetes; reduces test accuracy).
• ADA recommends screening for adults with diabetes age 50+ or with risk factors.
• Toe-brachial index (TBI) more accurate in adults with calcified arteries.

Treatment Stepwise

• Risk factor management:
  • Smoking cessation — single most important intervention.
  • Glucose control — A1C below 7%.
  • BP control — below 130/80 mmHg ideally.
  • LDL cholesterol below 70 mg/dL with statin.
  • Antiplatelet therapy (aspirin or clopidogrel).
• Supervised exercise therapy: 3 times weekly for 12 weeks; improves walking distance by 50-100% in many patients.
• Cilostazol (Pletal): 100 mg twice daily; improves walking distance by 40-60%; contraindicated in heart failure.
• Revascularization: angioplasty with or without stent for moderate-severe disease; bypass surgery for severe disease or anatomy not amenable to endovascular treatment.
• Wound care: aggressive treatment of non-healing ulcers; multidisciplinary team.
• Amputation: last resort for unsalvageable critical limb ischemia.

PAD as Cardiovascular Risk Marker

• Adults with PAD have 3-5 times higher cardiovascular mortality than non-PAD peers.
• The arterial disease affecting legs reflects systemic atherosclerosis.
• Coronary artery disease coexists in 50-70% of PAD patients.
• Cerebrovascular disease coexists in 30-40%.
• Aggressive cardiovascular risk management is essential.
• Statin therapy is recommended for nearly all adults with PAD.

The Diabetes-PAD Interaction

• Adults with both diabetes and PAD have substantially higher amputation rates.
• Neuropathy + PAD = “ischemic neuropathic foot” — silent ulcers with poor healing.
• Wounds may be non-painful but slow-healing.
• Multidisciplinary care (podiatry, vascular surgery, endocrinology) improves outcomes.
• Daily foot inspection is critical.
• Any wound or color change warrants urgent evaluation.

Prevention Strategies

• Smoking cessation — substantially reduces PAD progression.
• Glucose control — A1C below 7%.
• Blood pressure management — below 130/80.
• Statin therapy for adults with diabetes age 40+.
• Regular walking exercise.
• Weight management.
• Mediterranean-style eating pattern.
• ABI screening for adults with diabetes age 50+.
• Aspirin for adults with established cardiovascular disease or PAD.

Who Should Be Screened

• Adults with diabetes age 50 or older.
• Adults with diabetes age 40-49 with other risk factors (smoking, hypertension, dyslipidemia, family history).
• Any adult with diabetes and symptoms suggesting PAD.
• Adults with non-healing foot wounds.
• Adults with prior foot ulcers.
• Repeat ABI every 5 years if normal, more often if abnormal.

The Bottom Line

Peripheral artery disease is 2 to 4 times more common in adults with diabetes than in non-diabetic peers and is a major risk factor for foot ulcers, infections, and amputation. The diabetes-specific challenge is that peripheral neuropathy can mask the classic claudication pain — adults with both PAD and neuropathy may have severe disease with minimal symptoms. The ankle-brachial index (ABI) is the standard screening test; the ADA recommends ABI screening for adults with diabetes age 50+ or with risk factors. Treatment is stepwise: smoking cessation (most important intervention), glucose control, BP control, statin therapy with LDL below 70 mg/dL, antiplatelet therapy, supervised exercise programs, cilostazol for claudication, and revascularization (angioplasty, stenting, bypass) for moderate-severe disease. PAD is also a marker of systemic atherosclerosis — adults with PAD have 3-5 times higher cardiovascular mortality, requiring aggressive cardiovascular risk management. The combination of diabetes and PAD substantially increases amputation risk; multidisciplinary care with podiatry, vascular surgery, and endocrinology improves outcomes. For adults with type 2 diabetes managing long-term vascular health, smoking cessation, glucose control, and ABI screening at age 50+ are essential. See our broader diabetes heart attack risk guide for context on related cardiovascular disease.